Bluebird Bio, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
Joseph Vittiglio, Chief Business & Legal Officer of bluebird bio, Inc., has disposed of all his common stock holdings and restricted stock units following the company's merger with Beacon Parent Holdings, L.P., converting them into cash and contingent value rights.
Bluebird Bio director John O. Agwunobi converted his equity holdings, including restricted stock units, into cash and contingent value rights as the company completed its merger and became a wholly owned subsidiary of Beacon Parent Holdings, L.P.
Mark Vachon, a Director of bluebird bio, Inc., has reported the disposition of all his directly held common stock in the company, effective June 2, 2025, as a result of the previously announced merger with Beacon Parent Holdings, L.P.
Richard A. Colvin, Chief Medical Officer of bluebird bio, Inc., has reported the conversion of his equity holdings into cash and contingent value rights following the company's merger with Beacon Merger Sub, Inc.
A recent SEC Form 4 filing details bluebird bio Director Najoh Tita-Reid's share transactions, reflecting the company's acquisition by Beacon Parent Holdings, L.P. through a tender offer and subsequent merger.
bluebird bio's President and CEO, Andrew Obenshain, reported the conversion of his equity holdings into cash and contingent value rights as part of the company's acquisition by Beacon Parent Holdings, L.P.
Elisabeth Leiderman, a director at bluebird bio, Inc., reported the disposition of all her common stock holdings following the company's merger with Beacon Parent Holdings, L.P., effective June 2, 2025.
A recent SEC Form 4 filing reveals bluebird bio Director Charlotte Jones-Burton's stock transactions, detailing the conversion of her shares and restricted stock units in connection with the company's merger with Beacon Parent Holdings, L.P.
Form 4: Bluebird Bio Officer's Equity Converted as Company Completes Merger and Becomes Private Entity
Thomas J. Klima, Chief Commercial & Operating Officer of bluebird bio, Inc., converted his equity holdings into cash and contingent value rights as the company completed its merger and became a wholly-owned subsidiary.
bluebird bio's Chief Financial Officer, O. James Sterling, reported significant changes in his beneficial ownership of common stock, reflecting the recently completed merger where bluebird bio became a wholly-owned subsidiary of Beacon Parent Holdings, L.P.
Form 4: bluebird bio Director Nick Leschly Reports Full Share Disposition Following Merger Completion
Director Nick Leschly has reported the disposition of all his direct and indirect holdings in bluebird bio, Inc. common stock and restricted stock units, effective with the completion of the company's merger into a wholly-owned subsidiary of Beacon Parent Holdings, L.P.
Richard A. Paulson, a director at bluebird bio, Inc., reported the disposition of 1,323 common shares on June 2, 2025, following the completion of the company's merger with Beacon Merger Sub, Inc.
Form 4: bluebird bio Director Michael Cloonan Reports Final Share Disposal Following Merger Completion
Director Michael Cloonan has reported the disposal of all his bluebird bio shares, totaling 1,867, as a result of the company's merger with Beacon Parent Holdings, L.P. effective June 2, 2025.
Richard A. Colvin, Chief Medical Officer of bluebird bio, Inc., sold 584 shares of common stock on March 3, 2025, to cover tax withholding obligations.
Thomas Klima, Chief Commercial & Operating Officer of bluebird bio, sold 500 shares of common stock on March 3, 2025, to cover tax withholding obligations.
Andrew Obenshain, President and CEO of bluebird bio, Inc., sold 921 shares of common stock on March 3, 2025, to cover tax withholding obligations.
Andrew Obenshain, President and CEO of bluebird bio, acquired 763 shares of common stock following the vesting of a performance stock unit award.
Thomas Klima, Chief Commercial & Operating Officer of bluebird bio, sold 122 shares of common stock on February 3, 2025, to cover tax withholding obligations.
Richard A. Colvin, Chief Medical Officer of bluebird bio, Inc., sold 64 shares of common stock on February 3, 2025, to cover tax withholding obligations.
Joseph Vittiglio, Chief Business & Legal Officer of bluebird bio, sold 238 shares of common stock on February 3, 2025, to cover tax withholding obligations.
Andrew Obenshain, President and CEO of bluebird bio, Inc., sold 86 shares of common stock on February 3, 2025, to cover tax withholding obligations.
Richard A. Colvin, Chief Medical Officer of bluebird bio, Inc., sold 19 shares of common stock on January 6, 2025, to cover tax withholding obligations related to vesting Restricted Stock Units.
Andrew Obenshain, CEO of bluebird bio, sold shares of common stock on January 6, 2025, to cover tax withholding obligations related to the vesting of Restricted Stock Units.
Bluebird Bio's CEO, Andrew Obenshain, sold 971 shares of common stock at $0.4173 per share to cover tax obligations related to vesting restricted stock units.
Bluebird Bio's Chief Medical Officer, Richard A. Colvin, sold 2,824 shares of common stock at $0.4173 per share to cover tax obligations related to vesting restricted stock units.
Director Najoh Tita-Reid acquired shares and stock options in Bluebird Bio on November 6, 2024, as reported in a Form 4 filing.
Director Nick Leschly reports acquisition of Bluebird Bio shares and stock options, along with adjustments to beneficial ownership.
Director Richard Paulson acquired shares and options in Bluebird Bio on November 6, 2024, as reported in a Form 4 filing.
Form 4: Bluebird Bio Director Charlotte Jones-Burton Reports Acquisition of Shares and Stock Options
Director Charlotte Jones-Burton acquired shares and stock options in Bluebird Bio, Inc. on November 6, 2024, according to a Form 4 filing.
Director John O. Agwunobi of Bluebird Bio, Inc. acquired stock options and restricted stock units on November 6, 2024.